Back to Search
CATHERINE ZIELINSKI, PHARMD
PHARMD
Pharmacist
NPI: 1124417936Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
14852-40(WI)
Research & Publications (20)
The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
PMID 18191396·Eur J Cancer·2008
6-review
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
PMID 15735116·J Clin Oncol·2005
3-trial
Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
PMID 14768404·Oncology (Williston Park)·2003
6-review
Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers.
PMID 14572152·Breast Cancer Res Treat·2003
8-other
Gemcitabine/anthracycline combinations in metastatic breast cancer.
PMID 12057043·Clin Breast Cancer·2002
6-review
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.
PMID 19467222·Biochem Biophys Res Commun·2009
8-other
Third consensus on medical treatment of metastatic breast cancer.
PMID 19608616·Ann Oncol·2009
6-review
Cytoplasmic proteome and secretome profiles of differently stimulated human dendritic cells.
PMID 19351150·J Proteome Res·2009
8-other
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
PMID 19289619·J Clin Oncol·2009
3-trial
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
PMID 19389529·J Am Acad Dermatol·2009
5-case
Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.
PMID 19508170·Curr Cancer Drug Targets·2009
8-other
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
PMID 19171421·Cancer Lett·2009
8-other
Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells.
PMID 19222175·J Proteome Res·2009
7-preclinical
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
PMID 19232474·Cancer Treat Rev·2009
6-review
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
PMID 19042053·Lung Cancer·2009
3-trial
A phase II study of bortezomib in patients with MALT lymphoma.
PMID 19336742·Haematologica·2009
3-trial
Management of cardiac adverse events occurring with sunitinib treatment.
PMID 19443377·Anticancer Res·2009
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 11558 N PORT WASHINGTON RD
MEQUON, WI 53092 - Phone
- (262) 241-7983
Quick Facts
- NPI
- 1124417936
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile